Clearbridge LLC Has Boosted Alexion Pharmaceuticals INC (ALXN) Position

June 14, 2018 - By Jimmy Baldridge

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) LogoInvestors sentiment decreased to 1 in Q1 2018. Its down 0.03, from 1.03 in 2017Q4. It dropped, as 43 investors sold ALXN shares while 184 reduced holdings. 60 funds opened positions while 167 raised stakes. 200.94 million shares or 1.68% less from 204.38 million shares in 2017Q4 were reported. Cleararc stated it has 5,680 shares. Gsa Cap Partners Llp has 0.09% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Atlantic Tru Gru Ltd Co has invested 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Sumitomo Mitsui Asset Mngmt Co Ltd holds 0.03% or 15,284 shares in its portfolio. Aqr Lc reported 760,719 shares. Plante Moran Ltd Liability Com reported 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Sands Cap Mngmt Lc has 1.13% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 3.44M shares. Assetmark Incorporated reported 491 shares. Massmutual Fsb Adv holds 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 67 shares. 12 are held by Lazard Asset Mgmt Limited Liability. Nomura Asset Mngmt reported 0.04% stake. Fjarde Ap has invested 0.1% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Paradigm Asset Management Limited Com owns 550 shares. Huntington National Bank holds 0% or 301 shares. State Street has 9.11 million shares for 0.09% of their portfolio.

Since January 2, 2018, it had 1 buying transaction, and 16 insider sales for $4.25 million activity. Franchini Indrani Lall sold 1,459 shares worth $169,696. $1.54M worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by HANTSON LUDWIG. Clancy Paul J also sold $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, February 6. 655 shares were sold by Wagner Heidi L, worth $76,805. 1,625 shares were sold by O’Neill Julie, worth $194,723. $220,703 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by LAW ANNE-MARIE on Friday, June 8.

Clearbridge Llc increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 34.43% based on its latest 2018Q1 regulatory filing with the SEC. Clearbridge Llc bought 217,043 shares as the company’s stock declined 2.96% with the market. The institutional investor held 847,498 shares of the health care company at the end of 2018Q1, valued at $94.46 million, up from 630,455 at the end of the previous reported quarter. Clearbridge Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $26.74B market cap company. The stock increased 1.66% or $1.96 during the last trading session, reaching $120.16. About 990,288 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 19.53% since June 14, 2017 and is uptrending. It has outperformed by 6.96% the S&P500.

Clearbridge Llc, which manages about $5.40B and $4.49B US Long portfolio, decreased its stake in Synchrony Finl (NYSE:SYF) by 1.19 million shares to 2.68 million shares, valued at $89.71 million in 2018Q1, according to the filing. It also reduced its holding in Autozone Inc (NYSE:AZO) by 23,892 shares in the quarter, leaving it with 105,098 shares, and cut its stake in Adient Plc.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Streetinsider.com which released: “Alexion (ALXN)Says Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with PNH for Late-Breaking …” on June 14, 2018, also Businesswire.com with their article: “Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal …” published on June 14, 2018, Streetinsider.com published: “Alexion Pharma (ALXN), Complement Pharma Announce Pact to Co-Develop Pre-Clinical Complement Inhibitor for …” on June 11, 2018. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Schaeffersresearch.com and their article: “2 Biotech Stocks That Could Blast Off This Summer” published on June 04, 2018 as well as 247Wallst.com‘s news article titled: “Short Sellers Up the Ante For Major Biotechs” with publication date: June 12, 2018.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 14 analysts covering Alexion Pharmaceuticals (NASDAQ:ALXN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Alexion Pharmaceuticals had 24 analyst reports since December 18, 2017 according to SRatingsIntel. The rating was maintained by SunTrust with “Buy” on Monday, February 12. The firm earned “Buy” rating on Thursday, February 8 by Stifel Nicolaus. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Outperform” rating given on Thursday, January 4 by Raymond James. Evercore maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, May 8 with “Buy” rating. Credit Suisse reinitiated the shares of ALXN in report on Thursday, January 18 with “Outperform” rating. Piper Jaffray maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, May 8 with “Buy” rating. Robert W. Baird upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Monday, December 18 to “Outperform” rating. The firm has “Buy” rating by Piper Jaffray given on Thursday, February 8. The firm has “Buy” rating given on Thursday, March 15 by Robert W. Baird. Citigroup maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Friday, February 9. Citigroup has “Buy” rating and $170 target.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: